Claritev Corporation
NYSE:CTEVMedical - Healthcare Information Services
+$0.42 today
- Market cap
- $380.77M
- Beta
- 0.77
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$17.16
Volume 0.31M
Average 0.14M
CTEV Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Claritev CorporationNYSE: CTEV
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How CTEV compares with its peers on the latest reported figures
- CTEV's LTM Mar 2026 research & development of $0 is the 10th highest of the 11 companies compared; the peer median is $67.59M.
- Research & development amounts to 0.0% of revenue for CTEV, versus a peer median of 5.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $175.6M | +66.9% | +70.5% | 9222.6% | |
| LTM Mar 2026 | $146.28M | -4.6% | -13.1% | — | |
| LTM Mar 2026 | $122.39M | +7.2% | +18.8% | 21.1% | |
| LTM Mar 2026 | $120.06M | -3.1% | -5.4% | 15.2% | |
| LTM Mar 2026 | $97.75M | -13.6% | -0.7% | 5.9% | |
| LTM Sep 2026 | $37.43M | +37.4% | +8.7% | 14.0% | |
| LTM Mar 2026 | $13.97M | +11.6% | +2.3% | 3.7% | |
| LTM Mar 2026 | $7.53M | -25.4% | +35.2% | 3.4% | |
| LTM Mar 2026 | $3.31M | +25.5% | +9.3% | 3.8% | |
CTEVClaritev Corporation | LTM Mar 2026 | $0 | — | — | 0.0% |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CTEV) | $67.59M | +7.2% | +8.7% | 5.9% | |
Competitors are the stored peer set for CTEV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.12B | 1.08B | 961.52M | 930.62M | 965.41M |
| Cost of Revenue | 175.29M | 204.1M | 235.47M | 239.4M | 698.84M |
| Gross Profit | 942.31M | 875.62M | 726.06M | 691.22M | 266.58M |
| Gross Margin | 84.3% | 81.1% | 75.5% | 74.3% | 27.6% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 151.1M | 132.14M | 135.99M | 160.22M | 221.52M |
| Operating Expenses | 556.19M | 1.24B | 564.07M | 2.08B | 221.52M |
| Depreciation & Amortization | 412.06M | 415.66M | 425.79M | 436.44M | 448.45M |
| EBITDA | 814.99M | 158.32M | 651.93M | (1.01B) | 475.44M |
| EBITDA Margin | 72.9% | 14.7% | 67.8% | -108.3% | 49.2% |
| Operating Income | 386.12M | (362.73M) | 161.98M | (1.39B) | 45.06M |
| Operating Margin | 34.5% | -33.6% | 16.8% | -149.4% | 4.7% |
| Interest Income | 30K | 3.5M | 8.23M | 3.13M | 1.56M |
| Interest Expense | 267.48M | 303.4M | 333.21M | 326.37M | 400.07M |
| Other Income / Expenses | (250.67M) | (198.01M) | (269.04M) | (380.78M) | (418.14M) |
| Income Before Tax | 135.45M | (560.74M) | (107.06M) | (1.77B) | (373.08M) |
| Pre-Tax Margin | 12.1% | -51.9% | -11.1% | -190.3% | -38.6% |
| Income Tax Expense | 33.37M | 12.17M | (15.36M) | (124.88M) | (88.8M) |
| Net Income | 102.08M | (572.91M) | (91.7M) | (1.65B) | (284.28M) |
| Net Margin | 9.1% | -53.1% | -9.5% | -176.9% | -29.4% |
| EPS (Basic) | 6.40 | (35.87) | (5.69) | (101.92) | (17.30) |
| EPS (Diluted) | 6.40 | (35.87) | (5.69) | (101.92) | (17.30) |
| Weighted Avg Shares | 16.28M | 15.97M | 16.13M | 16.15M | 16.43M |
| Weighted Avg Shares (Diluted) | 16.29M | 15.97M | 16.13M | 16.15M | 16.43M |
Claritev Corporation
NYSE:CTEV
Intrinsic Alpha fair value
Locked
Current Price
$22.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.